Abstract
While studies have identified a number of mutations in mantle cell lymphoma (MCL), the list may still be incomplete and contribution to the pathogenesis remains unclear. We analyzed the mutational landscape of four mantle cell lymphoma biopsies obtained during an 8-year period from the same patient with his normal cells serving as control; we also established a cell line from the final stage of the disease. Numerous mutations with high allelic burden have been identified in all four biopsies. While a large subset of mutations was seen only in individual biopsies, the core of 21 mutations persisted throughout the disease. This mutational core is also maintained in the cell line that also displays DNA-methylation and cytokine secretion profiles of the primary mantle cell lymphoma cells. This cell line is uniquely sensitive to clinically relevant inhibitors of Bruton's Tyrosine Kinase. The response to Bruton Tyrosine Kinase's inhibition is enhanced by inhibitors of CDK4/6 and mTOR. Among the mutations seen in the primary and cultured MCL cells, mutations of three genes are involved in the control of H3K4 methylation: demethylase KDM5C, present already in the early disease, and methyltransferase KMT2D and cofactor BCOR, both of which are seen late in the disease and are novel and predicted to be pathogenic. The presence of these mutations was associated with hypermethylation of H3K4. Restoration of KDM5C expression affected expression of numerous genes involved in cell proliferation, adherence/movement, and invasiveness.
Highlights
Mantle cell lymphoma (MCL), a B-cell lymphoma with t(11:14) translocation involving the CyclinD1 (CCND1) gene [1], has typically poor prognosis [2]
To gain insight into gene mutations potentially involved in mantle cell lymphoma (MCL) development and progression, we performed whole-exome sequencing (WES) of four lymphoma biopsies obtained from the same patient 2– 4 years apart using the patient’s normal cells as a control
The second group was comprised of 21 common mutations that were present in essentially all biopsies, possibly reflecting the set of core mutations required to sustain the malignant nature of this MCL
Summary
Mantle cell lymphoma (MCL), a B-cell lymphoma with t(11:14) translocation involving the CyclinD1 (CCND1) gene [1], has typically poor prognosis [2]. DNA sequencing studies [3,4,5,6,7] in MCL identified diverse gene mutations; only a few affecting ATM, CCND1, and KMT2D (MLL-2) displayed a relatively high. We report that whole-exome sequencing (WES) of four different MCL specimens obtained from the same patient at different times identified a striking gene mutational pattern. While many of the tumor-specific, high-allelic frequency mutations were seen at only a single time point, 21 other mutations, many novel, persisted throughout the entire disease. These core mutations were preserved in a cell line we developed at late stage of the lymphoma.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.